TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01438463

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PURETHAL Mites 6,667 AU/ml
Description: Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PURETHAL Mites 20,000 AU/ml
Description: Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PURETHAL Mites 50,000 AU/ml
Description: Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PURETHAL Mites 100,000 AU/ml
Description: Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
Study: NCT04598906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual environment rehabilitation
Description: The participants attended 10-15 computer sessions during 6-12 weeks. Each session lasted 30 minutes and consisted of the set of virtual environment tasks (Shooting Range,Virtual Supermarket Shopping Task and Objects). Shooting range demands differentiation of targets from non-targets and focuses on training of selective attention, psychomotor speed and inhibition control. Virtual Supermarket Shopping requires memorizing the shopping list and searching for products in the supermarket area. Objects requires memorizing of the spatial and temporal context while searching for objects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual environment rehabilitation
Description: The participants attended 10-15 computer sessions during 6-12 weeks. Each session lasted 30 minutes and consisted of the set of virtual environment tasks (Shooting Range,Virtual Supermarket Shopping Task and Objects). Shooting range demands differentiation of targets from non-targets and focuses on training of selective attention, psychomotor speed and inhibition control. Virtual Supermarket Shopping requires memorizing the shopping list and searching for products in the supermarket area. Objects requires memorizing of the spatial and temporal context while searching for objects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paper-pencil rehabilitation
Description: The participants in the paper-pencil rehabilitation attended 10-15 paper pencil sessions for 6-12 weeks. Each session lasted 45 minutes. Each paper-pencil session starts with a warm-up game. The session continues with a set of paper-pencil tasks focused on attention, fine motor skills, recall, short-term and long-term memory, verbal fluency, visual search, cognitive flexibility, abstraction and executive functions, numerical abilities. The tasks are adapted according to the participant´s abilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paper-pencil rehabilitation
Description: The participants in the paper-pencil rehabilitation attended 10-15 paper pencil sessions for 6-12 weeks. Each session lasted 45 minutes. Each paper-pencil session starts with a warm-up game. The session continues with a set of paper-pencil tasks focused on attention, fine motor skills, recall, short-term and long-term memory, verbal fluency, visual search, cognitive flexibility, abstraction and executive functions, numerical abilities. The tasks are adapted according to the participant´s abilities.
Study: NCT03302871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hybrid training model of CIMT and BIT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Study: NCT03777553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy for Justice-Involved Veterans
Description: Behavioral intervention that uses narrative therapy and exposure to address repeated or complex trauma.
Study: NCT03216252

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: samples
Description: Blood samples, oral smear and urine
Study: NCT02515526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses
Description: Reference period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses
Description: Test period
Study: NCT03256760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Endotoxin

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03325608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POISED Care
Description: Program of dementia care management.
Study: NCT03170453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy
Description: An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
Study: NCT03049306

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol Oral Tablet
Description: Patients will receive Propranolol LA 80 mg PO at 7 PM before sleep (on CPAP withdrawal nights only)
Study: NCT03170453

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Supportive Therapy
Description: An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
Study: NCT03836911

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: serious game
Description: Effect of serious game on elderly in comparison of the physical activity adapted meeting

Intervention type: OTHER
Group type: OTHER
Intervention: classic program
Description: Effect of serious game on elderly in comparison of the physical activity adapted meeting
Study: NCT04289480

Intervention type: DEVICE
Intervention: ENTERPRISE 2 device
Description: The ENTERPRISE 2 Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms.
Study: NCT03049306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol Oral Tablet
Description: Patients will receive Propranolol LA 80 mg PO at 7 PM before sleep (on CPAP withdrawal nights only)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)
Study: NCT01286376

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Symbiotic Lactofos
Description: Lactobacillus Paracasei Lactobacillus Rhamnosus Lactobacillus Acidophilus Bifidobacterium lactis 12g/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin
Study: NCT00884884

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double Placebo
Description: 1 capsule daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole 15, placebo
Description: 15 mg Aripiprazole daily plus placebo daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole 7.5, Placebo
Description: Aripiprazole 7.5 mg daily plus Placebo daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 100, Placebo
Description: Topiramate 100 mg daily plus Placebo daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 200, Placebo
Description: Topiramate 200 mg daily plus Placebo daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 100, Aripiprazole 15
Description: Topiramate 100 mg daily plus Aripiprazole 15mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 100, Aripiprazole 7.5
Description: Topiramate 100 mg daily plus Aripiprazole 7.5mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 100, Aripiprazole 15mg
Description: Topiramate 100 mg daily plus Aripiprazole 15mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 200, Aripiprazole 7.5mg
Description: Topiramate 200 mg daily plus Aripiprazole 7.5mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 200, Aripiprazole 15
Description: Topiramate 200mg daily plus Aripiprazole 15mg daily
Study: NCT01568021

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention was administered in this study.
Study: NCT04160000

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Delivery of physical energy from external energy source via percutaneously inserted electrophysiologic catheter to destroy heart tissue in the human atrium and adjoining vasculature

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation
Description: Administration of antiarrhythmic drug to achieve either rate control or restoration of sinus rhythm for management of atrial fibrillation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of CardioMems Hemodynamic monitor
Description: Insertion of wireless hemodynamic monitor to provide hemodynamic data to guide heart failure therapy to achieve heart failure improvement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empiric heart failure drug therapy
Description: Administration of heart failure drug therapy based on clinical evaluation to achieve heart failure improvement.
Study: NCT01507753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Supplementation
Description: The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Supplementation
Description: The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Psychotherapy (PEP)
Description: Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Psychotherapy (PEP)
Description: Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
Study: NCT00390936

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Brivanib
Description: Tablet, Oral, Brivanib 300 mg, 600 mg, 800 mg, 1000 mg, once daily (cycle 1: Day 1, Day 8 - 35), more than 5 weeks depending on response/toxicity
Study: NCT01789229

Intervention type: OTHER
Intervention: Tumor tissue collection
Description: Tissue sample is collected during therapeutic intervention by a medical doctor/surgeon.~Frozen tissue sections are first transferred to Dept.of Pathology. Pathologist samples required tissue to obtain enough evidence for analysis/diagnosis.~Rest tumor material with or without malignant cells is tranferred to the lab for Molecular Oncology of Prof.Zeillinger.

Intervention type: OTHER
Intervention: Tumor tissue collection
Description: Tissue sample is collected during therapeutic intervention by a medical doctor/surgeon.~Frozen tissue sections are first transferred to Dept.of Pathology. Pathologist samples required tissue to obtain enough evidence for analysis/diagnosis.~Rest tumor material with or without malignant cells is tranferred to the lab for Molecular Oncology of Prof.Zeillinger.

Intervention type: OTHER
Intervention: Sampling of ascites and pleural effusion
Description: Samples of malignant ascites and/or malignant pleural effusion is only collected during therapeutic intervention from patients at inpatient care.
Study: NCT03675815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV) 800 milligram (MG) Oral Tablet
Description: 800 milligrams (mg) orally once daily for 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir (DRV) 800 milligram (MG) Oral Tablet
Description: 800 milligrams (mg) orally once daily for 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 MG Oral Tablet
Description: 100 mg orally once daily for 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir 100 MG Oral Tablet
Description: 100 mg orally once daily for 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N(t)RTIs
Description: Choice of N(t)RTIs determined by clinician guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 MG Oral Tablet
Description: 50 mg orally once daily for 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 MG Oral Tablet
Description: 50 mg orally once daily for 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF 300 MG Oral Tablet
Description: 300 mg orally once daily for 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3TC 300 MG Oral Tablet
Description: 300 mg orally once daily for 96 weeks. Choice of 3TC or FTC will be determined by clinician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC 200 MG Oral Cap
Description: 200 mg orally once daily for 96 weeks. Choice of emtricitabine or lamivudine will be determined by clinician
Study: NCT01789229

Intervention type: OTHER
Intervention: Sampling of ascites and pleural effusion
Description: Samples of malignant ascites and/or malignant pleural effusion is only collected during therapeutic intervention from patients at inpatient care.

Intervention type: OTHER
Intervention: Collecting urine samples
Description: Patient is asked to give a urine sample. Urine is collected in urine beaker.

Intervention type: OTHER
Intervention: Collecting urine samples
Description: Patient is asked to give a urine sample. Urine is collected in urine beaker.

Intervention type: OTHER
Intervention: Collecting urine samples
Description: Patient is asked to give a urine sample. Urine is collected in urine beaker.

Intervention type: OTHER
Intervention: Collecting saliva sample
Description: Saliva sample is collected by spatula from the mouth cavity of the patient.

Intervention type: OTHER
Intervention: Collecting saliva sample
Description: Saliva sample is collected by spatula from the mouth cavity of the patient.

Intervention type: OTHER
Intervention: Collecting saliva sample
Description: Saliva sample is collected by spatula from the mouth cavity of the patient.
Study: NCT04513626

Intervention type: DRUG
Group type: OTHER
Intervention: DORAVIRINE 100 MG [Pifeltro]
Description: Immediate switch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DORAVIRINE 100 MG [Pifeltro]
Description: Immediate switch
Study: NCT01889199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Flutamide 125 mg orally each 28 day cycle for 6 cycles

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally each 28 day cycle for 6 cycles
Study: NCT01789229

Intervention type: OTHER
Intervention: Collecting sputum
Description: Patient is asked to produce sputum into a 50ml lab tube.
Study: NCT04221490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Tricuspid Valve Replacement
Description: Replacement of the tricuspid valve through a transcatheter approach
Study: NCT01789229

Intervention type: OTHER
Intervention: Collecting sputum
Description: Patient is asked to produce sputum into a 50ml lab tube.

Intervention type: OTHER
Intervention: Collecting sputum
Description: Patient is asked to produce sputum into a 50ml lab tube.

Intervention type: OTHER
Intervention: Collecting stool samples
Description: Stool samples are collected prior to bowel preparation for colonoscopy. Device for sampling is provided to the patient.

Intervention type: OTHER
Intervention: Collecting stool samples
Description: Stool samples are collected prior to bowel preparation for colonoscopy. Device for sampling is provided to the patient.

Intervention type: OTHER
Intervention: Collecting stool samples
Description: Stool samples are collected prior to bowel preparation for colonoscopy. Device for sampling is provided to the patient.

Intervention type: OTHER
Intervention: Lavage/Irrigation
Description: Irrigation liquid is collected during routine therapeutic or diagnostic procedure, e.g. lavage of the uterine cavity and fallopian tubes of women scheduled for surgery.

Intervention type: OTHER
Intervention: Lavage/Irrigation
Description: Irrigation liquid is collected during routine therapeutic or diagnostic procedure, e.g. lavage of the uterine cavity and fallopian tubes of women scheduled for surgery.

Intervention type: OTHER
Intervention: Lavage/Irrigation
Description: Irrigation liquid is collected during routine therapeutic or diagnostic procedure, e.g. lavage of the uterine cavity and fallopian tubes of women scheduled for surgery.
Study: NCT03159065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilberry
Description: Fruit beverage with bilberry and fermented oatmeal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blackcurrant
Description: Fruit beverage with blackcurrant and fermented oatmeal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango
Description: Fruit beverage with mango and fermented oatmeal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beetroot
Description: Fruit beverage with beetroot and fermented oatmeal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rose hip
Description: Fruit beverage with rose hip and fermented oatmeal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose drink
Description: A reference glucose drink
Study: NCT00642499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: 2.5 mg to 40 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01199445

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Triple fortified extruded tice (Fe, Zn and vitamin A)
Description: Triple fortified extruded rice (Fe, Zn and vitamin A)will be mix at ratio of 1:50 with normal rice then give to children at school lunch meal for 60 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Triple fortified extruded tice (Fe, Zn and vitamin A)
Description: Triple fortified extruded rice (Fe, Zn and vitamin A)will be mix at ratio of 1:50 with normal rice then give to children at school lunch meal for 60 days.
Study: NCT01497951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aminolaevulinic acid
Description: Photodynamic therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Methylcellulose Placebo
Description: Methylcellulose
Study: NCT02177435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Hydrochlorothiazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03377179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC294640
Description: Two 250 mg capsules of ABC294640 will be taken twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 200 MG
Description: HCQ tablets will be taken at a dose that will be determined